Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations
This article summarizes the current pharmacological profile of mirvetuximab soravtansine and provides an expert opinion on pharmacological strategies for optimizing its safety and efficacy profile for the treatment of platinum-resistant ovarian cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Drugs & Pharmacology | Epithelial Cancer | Fallopian Tube Cancer | Ovarian Cancer | Ovaries | Peritoneal Cancer